Avacta Group PLC Avacta to present at the UK Investor Show
March 22 2017 - 5:00AM
RNS Non-Regulatory
TIDMAVCT
Avacta Group PLC
22 March 2017
22(nd) March 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to present at the UK Investor Show
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, is pleased to announce that
its Chief Executive, Alastair Smith, will be presenting at the UK
Investor Show on 1(s t) April 2017 at the QE2 Centre, Westminster,
London.
The UK Investor Show is the largest UK stock market event with
3,000 investors expected to attend.
Members of Avacta Group's management team will be at stand 37
during the day and Alastair Smith will be presenting at 16:00 in
the Winnifrith-Britten room.
For more information, including registration details, please
visit:
www.ukinvestorshow.com
ENDS
Notes to Editors
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207 220 0500
Geoff Nash / Giles Rolls www.finncap.com
- Nominated Adviser
Tim Redfern / Alice Lane
- Corporate Broking Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
WG Partners www.wgpartners.co.uk
David Wilson
Nigel Barnes
Claes Spang
Zyme Communications (Trade Tel: +44 (0)7787 502 947
and Regional Media) katie.odgaard@zymecommunications.com
Katie Odgaard
Tel: +44 (0) 203 727 1000
FTI Consulting (Financial avacta@fticonsulting.com
Media and IR)
Simon Conway / Natalie Garland-Collins
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is also commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGZFVMNGNZM
(END) Dow Jones Newswires
March 22, 2017 05:00 ET (09:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024